Perspective | Published:

The critical importance of basic animal research for neuropsychiatric disorders

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Quadrato G, Brown J, Arlotta P. The promises and challenges of human brain organoids as models of neuropsychiatric disease. Nat Med. 2016;22:1220–8.

  2. 2.

    Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13:1161–9.

  3. 3.

    Selye H. Stress and disease. Science . 1955;122:625–31.

  4. 4.

    Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry. 2005;66:5–13.

  5. 5.

    Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–88.

  6. 6.

    LeDoux JE, Pine DS. Using neuroscience to help understand fear and anxiety: a two-system framework. Am J Psychiatry. 2016;173:1083–93.

  7. 7.

    Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacol . 2008;33:2048–60.

  8. 8.

    Willner P. The chronic mild stress (CMS) model of depression: history, evaluation and usage. Neurobiol Stress. 2016;6:78–93.

  9. 9.

    Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.

  10. 10.

    Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185:1–10.

Download references

Funding and disclosure

Authors acknowledge support funding from NIMH grants: MH104184, MH108286, MH099910 (TLB); MH086828 (SMT); MH048404, MH115027 (BM), MH063266 (WAC), MH108665, MH110441, MH110925, MH117292 (KJR); MH051399, MH096890 (EJN), MH104261 (HA), MH087463, MH117964 (TA). In the past two years, Dr. Carlezon received payment as a consultant for Psy Therapeutics. The authors declare no competing interests.

Author information

Correspondence to Tracy L. Bale.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading